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Background: Development of breast cancer is a multistage process influenced by hormonal and environmental
factors as well as by genetic background. The search for genes underlying this malignancy has recently been highly
productive, but the etiology behind this complex disease is still not understood. In studies using animal cancer
models, heterogeneity of the genetic background and environmental factors is reduced and thus analysis and
identification of genetic aberrations in tumors may become easier. To identify chromosomal regions potentially
involved in the initiation and progression of mammary cancer, in the present work we subjected a subset of
experimental mammary tumors to cytogenetic and molecular genetic analysis.
Methods: Mammary tumors were induced with DMBA (7,12-dimethylbenz[a]anthrazene) in female rats from the
susceptible SPRD-Cu3 strain and from crosses and backcrosses between this strain and the resistant WKY strain.
We first produced a general overview of chromosomal aberrations in the tumors using conventional kartyotyping
(G-banding) and Comparative Genome Hybridization (CGH) analyses. Particular chromosomal changes were then
analyzed in more details using an in-house developed BAC (bacterial artificial chromosome) CGH-array platform.
Results: Tumors appeared to be diploid by conventional karyotyping, however several sub-microscopic
chromosome gains or losses in the tumor material were identified by BAC CGH-array analysis. An oncogenetic tree
analysis based on the BAC CGH-array data suggested gain of rat chromosome (RNO) band 12q11, loss of RNO5q32
or RNO6q21 as the earliest events in the development of these mammary tumors.
Conclusions: Some of the identified changes appear to be more specific for DMBA-induced mammary tumors and
some are similar to those previously reported in ACI rat model for estradiol-induced mammary tumors. The later
group of changes is more interesting, since they may represent anomalies that involve genes with a critical role in
mammary tumor development. Genetic changes identified in this work are at very small scales and thus may
provide a more feasible basis for the identification of the target gene(s). Identification of the genes underlying
these chromosome changes can provide new insights to the mechanisms of mammary carcinogenesis.
Keywords: BAC CGH-array, SPRD-Cu3, DMBA, Mammary tumor, Oncotree model* Correspondence: afrouz.behboudi@his.se
1Department of Clinical Genetics, Institute of Biomedicine, Sahlgrenska
Academy, University of Gothenburg, SE-40530 Göteborg, Sweden
5Systems Biology Research Centre, School of Life Sciences, University of
Skövde, SE-54128 Skövde, Sweden
Full list of author information is available at the end of the article
© 2012 Samuelson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Samuelson et al. BMC Cancer 2012, 12:352 Page 2 of 10
http://www.biomedcentral.com/1471-2407/12/352Background
Genetic aberrations such as deletions and amplifications
are known to be involved in tumor initiation and progres-
sion [1-3] and their analysis may provide valuable informa-
tion about regions of the genome harboring cancer-related
genes. Today, several techniques are available to detect
chromosomal copy number changes and aberrations,
namely Karyotyping (G-banding, resolution about 10
megabases, Mb) metaphase based Comparative Genome
Hybridization (M-CGH, resolution about 5 Mb) and
array-CGH. The BAC (bacterial artificial chromosome)
CGH-array technique uses a platform composed of gen-
omic DNA fragments cloned in BAC clones. This method
provides a reasonably high resolution (hundreds kilo-
bases, kb) and generates high signal to noise ratios [4,5].
Breast cancer is the most common cancer type affect-
ing women. Development of breast cancer is a multistage
process influenced by hormonal and environmental fac-
tors as well as by genetic background. The search for
genes underlying the disease has recently been highly
productive [6,7], but the etiology behind this complex
disease is not understood [8]. Several cancer genes have
been identified for hereditary breast cancer in human [6],
however, these genes account only for a minority, ap-
proximately 20%, of genetic risk in hereditary breast can-
cer [7]. The majority (over 70%) of the hereditary cases
are thought to be caused by the interactions of multiple
genes with low-penetrance and most of these genes
remain to be identified.
In studies using animal cancer models, heterogeneity
of the genetic background and environmental factors is
reduced and thus analysis and identification of genetic
aberrations in tumors may become easier. Genetic com-
ponent of mammary cancer susceptibility is particularly
obvious in the rat models, since different inbred strains,
each representing a defined and limited gene pool, ex-
hibit widely different susceptibility to both spontaneous
and induced mammary cancer [7,9,10]. There are inbred
strains that are almost completely resistant to mammary
cancer (e.g. COP, WKY), whereas others are extremely
cancer-prone (e.g. WF, SPRD, BUF, ACI). Although it
would be quite feasible to analyze the biology behind
spontaneously occurring mammary tumors in these
model systems, most researchers prefer to use tumor in-
duction with carcinogenic agents in order to reduce la-
tency time and increase incidence of tumor development
in the susceptible animals. Commonly used chemical
carcinogenic agents for this purpose are NMU (N-methyl-
nitrosurea) and DMBA (7,12-dimethylbenz[a]anthra-
zene). If given in proper dosage at a given time, these
chemicals will induce tumors in susceptible animals
(such as WF and SPRD) within a few weeks after induc-
tion, whereas animals from the resistant strains will not
be affected [9,11,12]. Similarly, chronic treatment of ACIrats with estradiol induces a high frequency of mammary
tumors, while resistant strains show no tumors in these
circumstances [10]. Experimental designs using these
models are being used in the search of genes responsible
for susceptibility or resistance to developing mammary
tumors as valuable tools for genetic studies of breast
cancer [7,10].
A major question in cancer genetics is whether certain
genomic imbalances are early events and thus the initial
force of tumorigenesis [3]. As many cancers have hetero-
geneous genetic causes, interpretation of data from gen-
etic analysis is found to be difficult. To this end,
mathematical methods may aid to determine order of
genetic events and thus help to define the pathogenic
road(s) taken in the tumor mass [13]. Based on the
accepted theory that cancer evolve clonally from a single
cell, mathematical analysis may offer guidance for identi-
fication of the possible initial deviation in the first cancer
cell as representative of starting event during tumorigen-
esis. This approach might additionally help to determine
the evolution of events rooted from this initial deviation
resulting in building of the tumor mass [14]. Advanced
mathematical data handling algorithms, such as onco-
genic tree models, can be used to analyze BAC array
data towards identification of important small-scale
changes during tumorigenesis [15].
In this study, we subjected a set of 52 DMBA-induced
rat mammary tumors to G-banding and M-CGH ana-
lyses. Based on the results, 28 of the tumors were
selected for a more detailed cytogenetic analysis using
an in-house developed BAC CGH-array platform. The
result was then used to construct an oncogenetic tree
model showing the possible initial events and the devel-
opment thereof, and the potential order of the observed
alterations as well as their correlation to each other
during development of these tumors.
Methods
Tumor induction with DMBA
SPRD-Cu3 is an inbred rat strain highly prone to de-
velop induced mammary tumors by a single dose of
DMBA at a certain age of life. WKY female rats, on the
other hand, are resistant to mammary tumor induction
with DMBA (described in detail elsewhere, [7,16,17]).
SPRD-Cu3 females were mated to WKY/E56 males
(hereafter WKY), and F1 males were backcrossed to fe-
male SPRD-Cu3 rats. Tumors were induced in female
rats from SPRD-Cu3 (n = 10), F1 (n = 32) and SPRD-
Cu3x(SPRD-Cu3xWKY) backcross progeny (n = 187) as
previously explained [18]. Briefly, at the age of 53–
58 days, female rats were given a single gastric dose of
65 mg/kg of DMBA dissolved in sesame oil, per kilo-
gram of body weight. Tumors were detected in the
mammary glands by weekly palpations after treatment.
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lated 19 weeks post-treatment or earlier in case of tumor
perforating the skin [18]. Tumors were surgically
removed from each animal and DNA was extracted. The
tumors were subjected to histological analysis and were
shown to be papillary adenocarcinomas, sometimes inva-
sive with a cribriform pattern as described earlier
[18,19]. A total of 52 mammary tumors, including 11
tumors from SPRD-Cu3, 6 tumors from F1 and 35
tumors from the backcross progeny were included in
this study (Table 1). All animal experiments had been
approved by the local ethical committee (Université
Libre de Bruxelles, Gosselies Belgium).
Cytogenetic analysis
To set up primary cell cultures, small pieces of 10 fresh
tumor tissues developed in inbred SPRD-CU3 were cul-
tured in Dulbecco´s Modified Eagle Medium (DMEM)
containing 10% fetal calf serum supplemented with Glu-
tamine and incubated with standard culture conditions.
Primary tumor cell cultures were successfully established
for all of the tumors. Chromosome preparations for
cytogenetic analysis were made as follows: colcemid
(0.05 g/mL,GibcoBRL, Life Technologies, Grand Island,
NY) was added to the tumor cell cultures during the
final 20–30 minutes before harvest. The cells were har-
vested by mitotic shake-off, pelleted by centrifugation,
and re-suspended in 0.075 M KCl at room temperature
for 30 minutes, Followed by a methanol-acetic acid fix-
ation as described previously [20]. The tumor metaphase
chromosomes were subjected to cytogenetic analysis
after G-banding.
M-CGH
M-CGH analysis for all 52 mammary tumors was carried
out as described before [21]. In short, equal amounts (1
μg) of test DNA and reference DNA (normal DNA) were
differently labeled by nick translation with biotin-16-
dUTP (Enzo, Roche) and digoxigenin-11-dUTP (Enzo,
Roche), respectively. Probe-DNA hybridizations were
performed on normal metaphase slides from rat embryo
cell cultures. The probe signals were detected with
avidin fluorescein isothiocyanate (FITC) (Vector Labora-
tories, Burlingame, CA) and rhodamin-digoxigenin
(Sigma, Saint Louis, MO). The chromosomes wereTable 1 Tumor material used in this study




Using DMBA, mammary tumors were induced in female rats from three different gecounterstained with DAPI, dissolved in Vectashield
mounting medium (Vector Laboratories). The fluores-
cence was recorded using the Leica DM RXA micros-
copy (Wetzlar, Germany) equipped with an incident light
fluorescence system, a HBO 100 W vapor mercury lamp,
and filter blocks, specific for either fluorochrome, DAPI,
or Texas red, in combination with the Leica Q-FISH
software developed for microphotography (Cambridge,
UK). The Leica CW4000 software package (Cambridge,
UK) was used to perform digital image analysis.
BAC CGH-array
For the purpose of this study, we developed an in-house
BAC CGH-array platform, consisting of over 600 BACs
that represented 17 chromosome arms. Selection of
chromosome segments was made based on the M-CGH
results in this study and we included all chromosome seg-
ments that showed, even slight, deviation from normal
CGH profile. We additionally included chromosome seg-
ments with potential implication in tumorigenesis identi-
fied in the previous studies on rat cancer models [22-27].
BAC clones were purchased (BACPAC RESOURCES, Oak-
land, CA), cultured and BAC clone DNA was extracted
according to the manufactures instructions. The BAC
DNA was then amplified using DOP-PCR (DOP-Primer1;
CCGACTCGAGNNNNNNCTAGAA, DOP-Primer2; CC
GACTCGAGNNNNNNTAGGAG, DOP-Primer 3; CCG
ACTCGAGNNNNNNTTCTAG), according to protocol
suggested by Fiegler and co-workers [28], PCR products
were purified and spotted to glass slides with six individual
spots for every BAC on each array.
Based on M-CGH results we selected a total of 28
tumor samples for BAC CGH-array analysis, including 4,
6, and 18 tumors from the SPRD-Cu3, F1 and the back-
cross genetic backgrounds, respectively (Table 1). Two
μg of each tumor and control (normal female liver)
DNA was labeled with Cy3 or Cy5, purified and co-
hybridized in equal amount on the arrays according to
instructions from the manufacture (Invitrogen, Carlsbad,
CA). The printing of the array slides, hybridization, wash
and scanning of the images were performed at the DNA
Microarray Resource Center at SCIBLU (Swegene
Centre for Integrative Biology at Lund University, Swe-
den; http://www.lth.se/sciblu/services/dna_microarrays/).
All data was transferred into the BASE 2.9 (BioArrayNumber of tumors analyzed by:
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(http://base.onk.lu.se/onk/) and analyzed.
Oncogenetic tree
Oncogenetic tree analysis was performed as previously
described [13,29]. This analysis is a mathematical meth-
odology that uses genetic data to depict the likely order
of genetic events occurring during tumorigenesis. We
used the Oncotrees software (http://www.ncbi.nlm.nih.
gov/CBBresearch/Schaffer/cgh.html) to calculate the
weight matrix for all pairs of events and to derive a
model tree using the maximum weight branching algo-
rithm, which finds the rooted tree where the sum of the
weights of all edges is maximized.
Results
In the present work, SPRD-Cu3, F1-cross and back-
crosses from SPRD-CU3 and WKY strains were used to
obtain a set of tumors with different genetic background.
Cytogenetic analysis of 10 primary mammary tumor cell
cultures derived from SPRD-CU3 female rats, all
revealed a diploid genome.
M-CGH analysis showed recurrent RNO10 and RNO12 and
RNO20 gains
Fifty-two DMBA-induced mammary solid tumors with dif-
ferent genetic backgrounds were analyzed with M-CGH.
For every tumor, 10–15 metaphases were analyzed and an
average fluorescence ratio (FR) curve per chromosome was
established. Aberrations were recorded for FR curves
when these curves displayed values equal to or below 0,85
as losses and equal to or above 1,15 as gains AdditionalFigure 1 Summary of the results from M-CGH analysis of 52 DMBA-in
(11 tumors), (SPRD-Cu3xWKY) F1 (6 tumors) and SPRD-Cu3x(SPRD-Cu
gray bars) and losses (light bars) are presented as percentage of tumors thfile 1: Table S1. For the majority of the chromosomes, the
M-CGH analysis profile revealed FR curves very close to
the midline along the entire chromosome, indicating a
near normal CGH profile in most of the tumors. However,
three chromosomes, RNO10, RNO12 and RNO20, dis-
played moderate gains in more than 20% of the tumors
(Figure 1), particularly in those derived from the inbred
SPRD-CU3 and the backcross animals (Additional file 1:
Table S1). RNO12 was the most recurrently altered
chromosome with gains in 25 (48%) of all tumors.
RNO10, and RNO20 gains were less common and were
present in 15 (29%) and 11 (21%) of the tumors, respect-
ively (Figure 1). Very few signs of losses were detected
among the tumors.
More detailed analysis of RNO10, RNO12 and RNO20
gains revealed that frequency of these genetic changes
varied among tumors derived from the three different
genetic backgrounds (data not shown). For instance,
RNO10 and RNO12 and RNO20 gains were detected in
tumors from SPRD-CU3 and the backcross animals,
whereas the F1 tumors only displayed gains of RNO10.
BAC CGH-array analysis confirmed and refined M-CGH
findings with a higher resolution
Based on the M-CGH results and availability of the ma-
terial, we selected a total of 28 tumors, including all the
26 tumors that displayed signs of chromosomal aberra-
tions plus two of those not showing any deviations as
controls, for detailed analysis using BAC CGH-array. We
developed an in-house BAC CGH-array covering 17
chromosome arms selected based on the results from the
M-CGH analysis and the previous studies on rat cancerduced mammary tumors developed in animals from SPRD-CU3
3xWKY) crosses (35 tumors). Frequency of chromosomal gains (dark
at displayed the aberration.
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repetitive DNA were excluded in order to reduce the risk
of false results. These included the centromeric and
outermost telomeric regions of all chromosomes plus the
heterochromatin regions at RNO1q12~q21, RNO3p,
RNO9q11~q12, RNO11p, RNO12p, RNO13p, and
RNO19p. Since RNO10, 12 and 20 displayed the most re-
current alterations (over 20%) in the M-CGH analysis we
chose an average distance between BAC clones of 0.46 to
0.92 Mb for these three chromosomes on the array. High
resolution BAC clone coverage was also prepared for
chromosome 4, 5 and 6, as earlier studies in our group re-
peatedly pinpointed to potential significance of aberra-
tions in these chromosomes in tumor development
[22,23,27]. For the rest of the chromosomes, BAC clone
coverage was less dense with an average distance of
3 Mb. BAC CGH-array analysis of 28 DMBA-induced
mammary tumors confirmed and extended the M-CGH
analysis results and revealed several recurrent chromo-
somal gains and losses, each including more than one
BAC. The eleven most frequent nonrandom aberrations
in the tumor material are summarized in Table 2. RNO20
was the most frequently altered chromosome and was the
only chromosome exhibiting both gains (in three regions)
and loss (in one region, Table 2). A new finding was fre-
quent chromosomal losses in RNO5q32 (in 20/28 of
tumors, 71%), which represented the second most recur-
rent alteration observed in the present work. Twenty-two
tumors showed gains at two different positions of
RNO12q making this chromosome the third most altered
chromosome in the tumor set. Gains of RNO10 occurred
with a frequency of 64% (in 18 cases) followed by loss of
RNO6q21 (53%, 15 cases) and RNO4q21 (21%, 6 cases).
As expected, the two control tumors with normalTable 2 The most recurrent chromosomal aberrations detecte
induced mammary tumors
















Based on Human 35 and Rat RGSC v3.4 genome build.karyotype showed a normal chromosome content in the
BAC CGH-array analysis. Results from the BAC CGH-
array analysis for tumors derived from different genetic
backgrounds are summarized in Figure 2.
Analysis of BAC CGH-array results by oncogenetic tree
identified early and late events
We performed an oncogenetic tree analysis on the BAC
CGH-array data from analysis of 28 tumors (Figure 3).
The analysis suggested gain of RNO12q11, and loss of
RNO5q32 and RNO6q21 as the earliest events in mam-
mary tumorigenesis in this material. In addition, gain of
RNO20q12 was placed as a very early deviation that
could occur either as a second event on the RNO12q11
path or as an independent initial single event. From the
initial event of RNO12q11 gain, a series of later genetic
events were branched, among which loss of RNO4q21
and RNO20q13 represented the latest deviations in this
path. From the initial event conferring loss of 5q32, gain
of 20p12 followed as a single node. Loss of RNO6q21
occurred as an isolated event branched independently
from the root (Figure 3).
Discussion
The exact molecular mechanisms responsible for the
onset and progression of breast cancer are still poorly
understood. Unlike the majorities of solid tumors, breast
cancer is usually associated with multiple small-scale
genetic alterations, including minor amplifications and
deletions in specific chromosomal regions. In the
present work, we combined classic cytogenetic analysis
(G-banding) with advanced molecular methodologies
(M-CGH and BAC CGH-array analysis), as well as





14q12, 7q22 15 (53%)









Figure 2 Incidence of the 11 most recurrent chromosomal gains (dark gray bar) and losses (light bars) as revealed by BAC CGH-array
analysis in tumor material. Results for the three tumor sets derived from different genetic backgrounds are reported separately. As shown,
tumors derived from the backcross animals in general displayed more aberrations compared to those derived from SPRD-CU3 and F1 animals.
Frequency of each aberration was also found to be different between the tumor sets.
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ment in DMBA-induced mammary tumors in a well-
defined rat model for the disease.
G-banding analysis of 10 tumors derived from inbred
SPRD-CU3 animals revealed a diploid karyotype in all.
This result is in concordance with previously reported
cytogenetic data for synthetic chemically (DMBA or
NMU)-induced rat mammary tumors [30-32], but con-
trasts with the reports from estradiol-induced ACIFigure 3 Order of genetic events predicted by maximum weight bran
analysis were included in this analysis. “r” represents the root, i.e. the norma
Numbers illustrated along the paths represent the number of tumors contr
lines represent the two possible alternative paths.mammary tumors [32,33]. M-CGH analysis of 52 tumors
from three different genetic backgrounds partly con-
firmed this observation and showed that most of the
chromosomes in the majority of tumors had profile
ratios quite close to the midline, indicating a close to
normal karyotype. However, recurrent segmental gains
were detected in three chromosomes; RNO10, RNO12
and RNO20 (Figure 1). This type of segmental gains can-
not be detected by G-banding due to the limitation ofching tree. The most frequent events identified by BAC CGH-array
l cell from which the oncotree (the pathogenic road) started.
ibuting to the development path that led to each node. The dashed
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group of the cells. When we studied the three tumor sets
derived from the different genetic backgrounds separ-
ately (data not shown), frequency of these genetic
changes appeared to vary among the tumor groups. For
instance, gain of RNO12 was the most common alter-
ation followed by RNO10 and RNO20 gains in tumor
groups derived from SPRD-CU3 and the backcross ani-
mals, whereas the F1 tumors exclusively displayed gains
of RNO10. The limited number of F1 tumors (six com-
pared to 11 SPRD-Cu3 and 35 backcross tumors) might
have affected this result, however, our data suggest that
the nature of genetic alterations might be influenced by
the genotype of the animals. In general, not many
chromosome losses were detected in the tumor panel
using this technique. This was most likely due to less
sensitivity of M-CGH technique in detecting segmental
chromosomal losses compared to chromosomal gains
[34]. Taken together, M-CGH analysis suggested a non-
random pattern of chromosome segment gains of
RNO10, RNO12 and RNO20 in the tumor material and
also implied that frequency of these aberrations varied in
the tumors developed in animals with different genetic
backgrounds.
To obtain a higher resolution of the genetic events, we
then performed BAC CGH-array analysis on a panel of
28 tumors selected based on the M-CGH data, including
all 26 tumors that displayed signs of chromosomal
changes and two tumors showing a normal M-CGH pro-
file. For the purpose of this analysis, we developed an in-
house BAC CGH-array platform designed to provide a
high density for chromosomal regions of interest. The
analysis confirmed and extended the M-CGH data and
refined the affected chromosome regions to a resolution
of about 150–300 Kb (i.e. the average size of the BAC
clones). We subsequently derived an oncogenetic tree
model based on the BAC CGH-array data, which sug-
gested four of the observed recurrent chromosomal
changes as possible initial events in mammary tumor de-
velopment in this model.
The most recurrent genetic changes were as follow:
– RNO5: Loss of RNO5q32 was the single most
recurrent segmental alteration detected in the BAC
CGH-array analysis of DMBA-induced mammary
tumors (in 20 tumors, 71%). RNO5q32 loss was not
detected by M-CGH due to less sensitivity of this
technique in detection of segmental losses [34]. This
event was moreover placed as one of the initial
events in the oncogenetic tree model, suggesting an
important role for the gene(s) located at this
chromosomal segment in the development of
DMBA-induced mammary tumors. RNO5q32 is
homologous to human chromosome 9p21 thatamong a number of important tumor suppressor
genes, harbors the CDKN2A/2B locus with its
deletion frequently reported in different cancer
types, including breast cancer [35]. This finding was
more intriguing, since M-CGH study of
estradiol-induced mammary tumors in ACI rats
similarly reported loss of RNO5 as the most
frequently observed somatic abnormalities that
usually occurred together with RNO20 losses [33].
Our preliminary BAC CGH-array analyses of a set
of ACI estradiol-induced mammary tumors
confirmed and extended this finding (unpublished
data). We thus conclude that deletion at this
chromosome segment might represent a common
signature of experimental mammary tumors
(irrespective of the genetic background and
the inducing agent) and thus may represent
an important genetic mechanism in breast
cancer development.
Remarkably, RNO5 is reported to carry mammary
cancer susceptibility QTLs (Mcs5, Mcstm1, Emca1,
and Emca8) in different rat mammary tumor models
that control multiplicity, incidence and/or latency of
tumors [7,36-38]. Some of these QTLs are shared
between strains and thus appear in different crosses,
while others are specific to one cross or limited to a
few crosses [7]. In general QTLs cover large
chromosome intervals and therefore identification of
the gene(s) responsible for the phenotype is difficult.
Recurrent RNO5q32 losses detected in this model
might explain some of the reported QTLs and as the
genetic changes identified in this work are at very
small scale, identification of the target gene(s) might
be more feasible.
– RNO20: Four separate recurrent chromosomal
aberrations were detected in RNO20, including
three regions of recurrent gains (RNO20p11, 20p12
and 20q12) and one region of recurrent loss
(RNO20q13). Together, these regions make RNO20
the most frequently affected chromosome in this
investigation. In the oncogenic tree model,
RNO20p11 and RNO20p12 gains were placed close
to the root, but as secondary events after
RNO12q11 gain and RNO5q32 loss, respectively
(Figure 3). The third gained chromosomal segment
at cytogenetic band RNO20q12 was placed as an
alternative path prior to the RNO12q11 gain and
thus might represent an early and important event
in the development of DMBA-induced mammary
tumors. Loss of RNO20q13 was placed as one of the
latest events in the RNO12q11 path and thus might
be of less importance in this model. Interestingly,
M-CGH analysis of ACI estradiol-induced
mammary tumors [33] showed that recurrent
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In our study, we did not reach a similar
conclusion; instead we found evidence for
correlation of RNO20p12 gain and RNO5q32 loss
in a sizable proportion of tumors. We suggest that
RNO20 gains (RNO20p11, 20p12 and 20q12) might
be more specific to the DMBA-induced mammary
tumor model. Since these aberrations were present
in a substantial proportion of experimental
mammary tumors, we suggest that RNO20 gains
might represent another key group of genetic
changes in mammary cancer development. Gains
of the homologous human chromosome regions
(6p21 and 6q21) might be implicated in breast
cancer development, at least in a group of patients.
– RNO6q21 loss and RNO12q11 gain were the next
most frequently observed chromosome aberrations
in this material, each observed in 15 of the tumors
(53%). In the oncogenic tree model, RNO6q21 loss
was branched independently from the root, defining
a subgroup of tumors independent from those with
RNO5q32 deletion or RNO12q21 gain (Figure 3).
Our finding was more intriguing, since M-CGH
analysis of ACI estradiol-induced rat mammary
tumors [33], reported similar finding of a recurrent
aberration involving proximal gain and distal loss of
RNO6 that never occurred in combination with
RNO5 loss.
Our result thus suggests that the genetic pathways
(at least those involving genes located at RNO5q32
and RNO6q21) related to tumor formation in
DMBA-induced rat mammary tumor are
comparable to those in the ACI estradiol-induced
rat model. RNO6q21 is homologous to parts of
human chromosome 14q12 and 7q22. The human
chromosome segment 7q22 contains an evolutionary
breakpoint between the rat and human lineage.
Deletion in this region is frequently reported as a
primary breakpoint in cancer and has been
suggested to be due to the fragility of this particular
segment [39].
– RNO12q11 gain was found as the third initial event
branching from the root in the oncogenic tree
model (Figure 3). This event was additionally placed
as secondary event after an alternative path initiated
by RNO20q12 gain in the oncogenic tree (Figure 3).
There were two overlapping BACs in this
chromosome segment in BAC CGH-arrays, both
showing gains in a substantial subset of tumors.
The gene Mafk (v-maf musculoaponeurotic
fibrosarcoma oncogene family, protein K) is located
in both of these clones suggesting that the Mafk
gene might be the potential target. Mafk is known to
be involved in transcription regulation and itsimplication has already been suggested in pancreatic
cancer [40].
– Finally, gain of RNO10 (at 10q12 and 10q24)
appeared along the pathogenic road initiated by gain
of RNO12q11 in the oncogenic tree (Figure 3). In all
crosses, RNO10 gains were found at cytogenetic
bands RNO10q12 and RNO10q24, each segment
including several BACs.
Conclusions
Taken together, M-CGH analysis suggested RNO10, 12
and 20 gains as the most recurrent chromosomal changes
among tumors. BAC CGH-array analysis confirmed this
finding and extended it by refining the affected chromo-
some segments to a resolution of about 150–300 Kb.
However, the identified genetic background-specific
chromosomal gains by M-CGH analysis were not con-
firmed by BAC CGH-array data. This could be due to the
limited number of tumors derived from SPRD-Cu3 and F1
animals in the tumor panel that was used for the BAC
CGH-array analysis. BAC CGH-array analysis could add-
itionally identify recurrent chromosome segment losses,
which could not be detected by M-CGH. This can be
explained by substantially higher resolution and sensitivity
of this technique, when compared to M-CGH. It is im-
portant to note that for BAC CGH-array analysis, we
selected a panel of 28 tumors based on M-CGH results,
including all the 26 tumors with signs of chromosomal
aberrations and two control tumors with normal chromo-
some profiles. Although the two control tumors did not
show any chromosome aberrations in the BAC CGH-
array analysis, there is still a possibility that among the
remaining 24 tumors, there existed tumor(s) with minor
aberrations (not detectable by M-CGH and thus excluded
from the analysis) that might have been overlooked.
In summary, we identified recurrent sub-microscopic
chromosome gains and losses in diploid SPRD-CU3
DMBA-induced mammary tumors. Using oncogenic tree
analysis, we classified these aberrations to early and late
events. Some of the chromosome anomalies, including
gains in three independent minimal segments of RNO20
(RNO20p11. 20p12 and 20q12) and in a small segment
of RNO 12q11, appeared to be more specific to this
tumor model, since they have not been reported in other
mammary tumor models [33]. Since these aberrations
were observed in a substantial number of tumors and
also the oncogenic tree analysis identified them as early
events, we suggest that they may represent a key group
of genetic changes with potential implication in breast
cancer development, at least in a subgroup of patients.
RNO12q11 was represented in the array by two over-
lapping BACs, both harboring the Mafk gene, whose
implication has earlier been reported in pancreatic
cancer [40].
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http://www.biomedcentral.com/1471-2407/12/352Another group of chromosome anomalies, namely
RNO5q32 and RNO6q21 losses, are similar to those
found in ACI estradiol-induced mammary tumors [33].
Since these chromosome aberrations are strain- and in-
ducing agent-independent and again were placed as early
events in the oncogenic tree, they seem critical to mam-
mary tumor development.
Identifying the genes underlying chromosome changes
found in the present work should help in understanding
biological mechanisms involved in mammary develop-
ment. Genetic changes identified in the present work are
at very small scale and may thus make identification of
the potential target gene(s) more feasible. Such studies
should yield both genetic and biological information use-
ful to understanding of human breast cancer.
Additional file
Additional file 1: Table S1. M-CGH analysis results in all 52 tumors.
Summary of the results is presented in Figure 1.
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